4 results match your criteria: "Univ. Toulouse III Paul Sabatier-ERL5294 CNRS[Affiliation]"
Front Immunol
July 2023
Cancer Research Center of Toulouse (CRCT), UMR1037 Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France.
Despite the advancements in therapy for B cell malignancies and the increase in long-term survival of patients, almost half of them lead to relapse. Combinations of chemotherapy and monoclonal antibodies such as anti-CD20 leads to mixed outcomes. Recent developments in immune cell-based therapies are showing many encouraging results.
View Article and Find Full Text PDFPharmacol Res
May 2017
Institut Claudius-Regaud, IUCT-O, Department of Pharmacology, Toulouse F-31059, France; CRCT, INSERM UMR1037, Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse F-31037, France. Electronic address:
Pharmacol Res
August 2016
Institut Claudius-Regaud, IUCT-O, Department of Pharmacology, Toulouse F-31059, France; CRCT, INSERM UMR1037, Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse F-31037, France. Electronic address:
We hypothesized that pazopanib is an inhibitor of cisplatin renal transporters OCT2, MATE1 and MATE2-K based on previous studies demonstrating an interaction between tyrosine kinase inhibitors and these transporters. Because several combinations of targeted therapies and cytotoxics are currently in development for cancer treatment, such an interaction is worth investigating. Experiments on HEK293 cells stably transfected to express OCT2, MATE1, MATE2-K or an empty vector (EV) were conducted.
View Article and Find Full Text PDFBlood Cancer J
January 2016
CRCT, UMR1037, Inserm-Univ. Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France.